专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019108928A1 MUCOADHESIVE NANOPARTICLE ENTRAPPED INFLUENZA VIRUS VACCINE DELIVERY SYSTEM 审中-公开
公开(公告)号：WO2019108928A1
公开(公告)日：2019-06-06
申请号：PCT/US2018/063299
申请日：2018-11-30
申请人： OHIO STATE INNOVATION FOUNDATION
发明人： GOURAPURA, Renukaradhya , DHAKAL, Santosh , RENU, Sankar
IPC分类号： A61K9/107 , A61K9/113 , A61K39/00 , A61K39/385 , A61K39/39
CPC分类号： A61K39/12 , A61K9/0043 , A61K9/5161 , A61K2039/541 , A61K2039/552 , A61K2039/55555 , A61K2039/55583 , A61K2039/57 , A61P31/16 , C12N2760/16134
摘要： Disclosed herein are nanoparticles comprising chitosan and an inactivated influenza A virus (IAV) antigen, wherein the chitosan encapsulates the inactivated IAV antigen. In some embodiments, the nanoparticle further comprises tripolyphosphate. In some embodiments, the nanoparticle reduces nasal shedding of an influenza A virus. In some embodiments, the nanoparticle elicits an increased amount of IgA antibody in a subject. Also disclosed are methods of reducing transmission of an influenza A virus, and methods of eliciting an immune response against an influenza A virus, in a subject compared to a control comprising administering to the subject a nanoparticle comprising chitosan and an inactivated influenza A virus (IAV) antigen, wherein the chitosan encapsulates the inactivated IAV antigen.

2. 发明申请

WO2019006022A1 SYSTEMS AND METHODS FOR MHC CLASS II EPITOPE PREDICTION 审中-公开
公开(公告)号：WO2019006022A1
公开(公告)日：2019-01-03
申请号：PCT/US2018/039843
申请日：2018-06-27
申请人： THE BROAD INSTITUTE, INC. , THE GENERAL HOSPITAL CORPORATION , XAVIER, Ramnik
发明人： XAVIER, Ramnik , GRAHAM, Daniel B. , LUO, Chengwei
IPC分类号： G06F19/22 , A61K39/00 , A61K39/02 , A61K38/10 , A61K35/15 , C07K7/08
CPC分类号： A61K39/02 , A61K2039/57 , A61K2039/605 , A61P31/04 , C07K14/195 , G01N33/68 , G01N2333/52 , G01N2333/5428 , G01N2333/545 , G01N2333/57 , G01N2800/24 , G06N3/0454 , G06N3/084
摘要： A system and method for prediction of immunodominant epitopes is provided herein. MHCII peptidomics was used to discover complex bacterial epitopes and host antigen processing pathways. Novel insights into the features of antigenicity are leveraged to build an algorithm for prediction of immunodominant epitopes. Use of immunodominant epitopes is described.

3. 发明申请

WO2018204760A1 CTLA4 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY 审中-公开
公开(公告)号：WO2018204760A1
公开(公告)日：2018-11-08
申请号：PCT/US2018/031049
申请日：2018-05-04
申请人： WEINER, David , MUTHUMANI, Kar , DUPERRET, Elizabeth , WISE, Megan
发明人： WEINER, David , MUTHUMANI, Kar , DUPERRET, Elizabeth , WISE, Megan
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2818 , A61K39/001157 , A61K39/3955 , A61K2039/507 , A61K2039/54 , A61K2039/57 , A61K2039/585 , A61P35/00 , C07K16/2866 , A61K2300/00
摘要： Disclosed herein is an immunogenic composition comprising at least an antigen and CTLA4 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the immunogenic composition to the subject in need thereof.

4. 发明申请

WO2017153955A1 USE OF ANTI-MCAM ANTIBODIES FOR TREATMENT OR PROPHYLAXIS OF GRANULOMATOUS LUNG DISEASES 审中-公开
公开(公告)号：WO2017153955A1
公开(公告)日：2017-09-14
申请号：PCT/IB2017/051402
申请日：2017-03-09
申请人： PROTHENA BIOSCIENCES LIMITED
发明人： FLANAGAN, Kenneth , HAMZEH, Nabeel
IPC分类号： C07K16/30
CPC分类号： C07K16/3092 , A61K2039/505 , A61K2039/57 , C07K2317/24 , C07K2317/34 , C07K2317/75 , C07K2317/92
摘要： The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of chronic beryllium disease (CBD), Blau syndrome or hot tub lung disease, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of granulomatous lung diseases.

5. 发明申请

WO2017129790A1 METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：用于治疗癌症的方法和药物组合物
公开(公告)号：WO2017129790A1
公开(公告)日：2017-08-03
申请号：PCT/EP2017/051844
申请日：2017-01-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： LEVADE, Thierry , SEGUI, Bruno , MEYER, Nicolas , COLACIOS VIATGÉ, Céline , ANDRIEU-ABADIE, Nathalie , BERTRAND, Florie
IPC分类号： A61K39/395 , C07K16/24 , C07K16/28 , A61K39/00
CPC分类号： A61K39/39558 , A61K2039/507 , A61K2039/57 , C07K16/241 , C07K16/2818 , C07K16/2878 , A61K2300/00
摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.
摘要翻译：本发明涉及用于治疗癌症的方法和药物组合物。具体而言，本发明涉及作为癌症治疗方案的一部分，增强施用于受试者的免疫检查点抑制剂的效力的方法，所述方法包括：向受试者施用药学有效量的TNFα阻断剂与免疫检查点抑制剂联合使用。

6. 发明申请

WO2017095324A1 CLINICAL CORRELATES OF IMMUNOTHERAPY EFFICACY 审中-公开
标题翻译：免疫疗效的临床相关性
公开(公告)号：WO2017095324A1
公开(公告)日：2017-06-08
申请号：PCT/SG2016/050441
申请日：2016-09-09
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , TESSA THERAPEUTICS PTE. LTD. , SINGAPORE HEALTH SERVICES PTE. LTD.
发明人： CONNOLLY, John , HOPKINS, Richard , TOH, Han Chong
IPC分类号： C12Q1/68 , G01N33/574 , A61K35/17 , A61P35/00
CPC分类号： A61K39/245 , A61K35/17 , A61K2039/5158 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C12N7/00 , C12N2710/16234 , C12N2710/16271 , C12Q1/68 , C12Q1/6886 , C12Q1/701 , C12Q1/705 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/574 , G01N33/57407 , G01N33/57423 , G01N33/57438 , G01N33/57446 , G01N2333/05 , G01N2333/521 , G01N2333/57 , G01N2800/52
摘要： A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT, wherein the disease is preferably a disease caused or exacerbated by infection with Epstein-Barr virus (EBV), such as EBV-positive nasopharyngeal carcinoma (NPC). Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT, preferably EBV-positive NPC.
摘要翻译：公开了一种用于预测患者是否将成为通过过继性细胞转移（ACT）治疗疾病的长期存活者的方法，其包括：（i）分析从以下获得的血液来源的样品：所述患者针对ACT治疗疾病的长期存活的一个或多个预后标记物，以及; （ii）基于步骤（i）的分析，预测患者是否是ACT治疗该疾病的长期存活者，其中该疾病优选是由Epstein-Barr病毒感染引起或加剧的疾病（ EBV），如EBV阳性鼻咽癌（NPC）。还公开了通过ACT治疗患者的方法，选择ACT治疗患者的方法以及选择ACT治疗疾病的患者，优选EBV阳性NPC的方法。

7. 发明申请

WO2017027843A1 CELL SURFACE COUPLING OF NANOPARTICLES 审中-公开
标题翻译：纳米颗粒的表面耦合
公开(公告)号：WO2017027843A1
公开(公告)日：2017-02-16
申请号：PCT/US2016/046891
申请日：2016-08-12
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , IRVINE, Darrell, J. , ZHENG, Yiran , TANG, Li
发明人： IRVINE, Darrell, J. , ZHENG, Yiran , TANG, Li
IPC分类号： A61K9/127 , A61K39/00 , A61K39/395
CPC分类号： A61K47/48823 , A61K9/127 , A61K39/0011 , A61K47/60 , A61K47/6849 , A61K47/6889 , A61K47/6903 , A61K47/6913 , A61K2039/505 , A61K2039/5158 , A61K2039/57 , A61K2039/585 , C07K14/5443 , C07K14/55 , C07K14/70503 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K14/70589 , C07K14/7155 , C07K16/2806 , C07K16/2845 , C07K16/289 , C07K16/30 , C07K19/00 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C12N5/0636
摘要： The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor.
摘要翻译：在一些实施方案中，本公开涉及包含具有非内在受体的细胞的方法和组合物，以及用与非内在受体结合的配体表面修饰的纳米颗粒。

8. 发明申请

WO2017021540A1 IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES 审中-公开
标题翻译： IL2RBETA /通用GAMMA链抗体
公开(公告)号：WO2017021540A1
公开(公告)日：2017-02-09
申请号：PCT/EP2016/068780
申请日：2016-08-05
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , CLEGG, Richard Ian
发明人： WANG, Cheng-I , BRAUER, Peter , YEO, Siok Ping , TAN, Hwee Ching , CONNOLLY, John Edward
IPC分类号： C07K16/28 , C07K16/46 , A61K39/00
CPC分类号： A61K39/3955 , A61K2039/505 , A61K2039/57 , C07K16/2866 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/64 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
摘要翻译：公开了抗CD122和/或γc抗体及其片段。还公开了包含这种抗体和片段的组合物，以及使用它们的用途和方法。

9. 发明申请

WO2017013421A1 TREATMENT OF CANCER BY INFUSION OF ONCOLYTIC HERPES SIMPLEX VIRUS TO THE BLOOD 审中-公开
标题翻译：通过将肠道病毒感染的方法浸入血液中治疗癌症
公开(公告)号：WO2017013421A1
公开(公告)日：2017-01-26
申请号：PCT/GB2016/052177
申请日：2016-07-19
申请人： VIRTTU BIOLOGICS LIMITED
发明人： CONNER, Joe
IPC分类号： A61K35/763 , A61K9/00 , A61K39/395 , A61K35/768 , A61K45/06 , A61P35/00
CPC分类号： A61K35/763 , A61K9/0019 , A61K9/08 , A61K35/768 , A61K39/3955 , A61K45/06 , A61K47/12 , A61K2039/57 , C07K16/2818 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： An oncolytic herpes simplex virus is disclosed for use in a method of treating cancer in a human subject, the method comprising administering to the human subject at least one dose of oncolytic herpes simplex virus by infusion to the blood, wherein the oncolytic herpes simplex virus reaches cells of the cancer in which it replicates.
摘要翻译：公开了一种用于治疗人类受试者的癌症的方法的溶瘤性单纯疱疹病毒，所述方法包括通过向血液输注至少一种剂量的溶瘤性单纯疱疹病毒，其中溶瘤性单纯疱疹病毒达到它复制的癌症细胞。

10. 发明申请

WO2016161391A3 POROUS SILICON MICROPARTICLE-BASED CANCER VACCINES AND METHODS FOR POTENTIATING ANTI-TUMORAL IMMUNITY 审中-公开
标题翻译：多孔硅微孔癌疫苗和潜在抗肿瘤免疫的方法
公开(公告)号：WO2016161391A3
公开(公告)日：2016-12-29
申请号：PCT/US2016025757
申请日：2016-04-01
申请人： THE METHODIST HOSPITAL
发明人： SHEN HAIFA , XIA XIAOJUN , FERRARI MAURO
IPC分类号： A61K39/00 , A61K39/12 , A61K47/48
CPC分类号： A61K39/0011 , A61K39/12 , A61K47/6923 , A61K2039/5154 , A61K2039/55555 , A61K2039/57 , C12N2770/24134
摘要： Porous silicon (pSi) microparticles (PSM) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent PSM-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies. The PSM of the present invention are also useful in developing other types of vaccines, including those not necessarily related to the treatment of cancers, such as vaccines for the treatment of acne, Alzheimer's disease, asthma, atherosclerosis, autoimmune disorders, autoinflammatory disease, celiac disease, colitis, Crohn's disease, diabetes, glomerulonephritis, infectious diseases, inflammatory bowel disease, irritable bowel syndrome, ischemia, Lupus, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, and related illnesses.
摘要翻译：公开了多孔硅（pSi）微粒（PSM），其在癌症免疫治疗剂和分子纳米医学领域提供了重要进展。特别地，针对基于树突状细胞的疫苗组合物公开了有效的基于PSM的佐剂，以及用于各种癌症免疫治疗的方法。本发明的PSM还可用于开发其他类型的疫苗，包括不一定与癌症治疗相关的疫苗，例如用于治疗痤疮的疫苗，阿尔茨海默氏病，哮喘，动脉粥样硬化，自身免疫性疾病，自身炎性疾病，腹腔镜疾病，结肠炎，克罗恩病，糖尿病，肾小球性肾炎，感染性疾病，炎性肠病，肠易激综合征，局部缺血，狼疮，盆腔炎，再灌注损伤，类风湿性关节炎，结节病，移植排斥和相关疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式